Featured Myeloma Treatments

There are nearly 100 treatments being tested in clinical trials around the US for myeloma patients. It can be a confusing and difficult task to find a trial or treatment that may be right for you. Below is a list of featured treatments to help you get started. If you have questions, you can call us or create an account today and we'll help you better understand your clinical trial options.

Create Your Account

Create your account today and get matched to myeloma treatments and trials around the US.

  • Find treatments with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new treatments become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

Selinexor

Selinexor is the first in a new class of drugs being investigated as a treatment for myeloma. It belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.

Learn more about this treatment


T Cells

A T cell or T lymphocyte is a type of lymphocyte (a subtype of white blood cell) that plays a central role in cell-mediated immunity.

Learn more about this treatment


Daratumumab DARZALEX®

Daratumumab is a drug used for the treatment of multiple myeloma. It is for use in people who have multiple myeloma who have already received at least one prior therapy. It is given as an injection into a vein through an IV.

Learn more about this treatment


RO6870810

RO6870810 is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs called Bromodomain and Extra-Terminal Protein (BET) Inhibitors.

Learn more about this treatment


Autologous Transplant

Autologous Transplant is a type of stem cell transplant that utilizes the patient's pre-collected own stem cell to rescue the bone marrow from the toxic effect of a very high dose chemotherapy.

Learn more about this treatment


CLR 131

CLR 131 is an investigational compound under development for a range of hematologic malignancies. It is currently being evaluated in a Phase I and Phase II clinical trial in patients with relapsed or refractory hematological diseases.

Learn more about this treatment


Natural Killer (NK) Cells

Natural Killer Cells can work in cancer treatment by being modified to recognize and attack tumor cells in the body. Natural Killer Cells are already found in the body, and are unique because they are able to recognize and attack cells without being acted upon by an antigen (immunization).

Learn more about this treatment


Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

Learn more about this treatment


Monoclonal Antibody

Antibodies are cloned and used to attack one specific type of protein found in cancer cells.

Learn more about these treatments


Immunotherapy

Immunotherapy involves the use of many active agents such as cells, cytokines or vaccines (among others). These agents are used to induce, enhance or suppress the function of the immune system.

Learn more about these treatments


Antibody Drug Conjugates

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.

Learn more about these treatments


SGN-CD48A

SGN-CD48A is a novel humanized anti-cd48 antibody-drug conjugate being tested for the treatment of multiple myeloma.

Learn more about this treatment


Bispecific Antibody

A bispecific antibody is a drug that has been designed to simultaneously target two different antigens. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells. This approach gives additional options in targeted immunotherapy and may help the immune system find and kill the cancer cells.

Learn more about these treatments


CAR2 Anti-CD38 A2 CAR-T Cells

CAR2 Anti-CD38 A2 CAR-T Cells has the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity. CAR2 Anti-CD38 A2 CAR-T Cells are being evaluated in multiple myeloma (MM) and has successfully demonstrated strong preclinical anti-tumor activity in animal models.

Learn more about this treatment

;